Assessing Effects of Treatment With Lisdexamfetamine Dimesylate for Pediatric ADHD Using a Parental Survey

Antonucci, Donna; Kunins, Craig; Manos, Michael J.; López, Frank A.; Kerney, Donna

doi:10.1017/s1092852900000080

Cited by 4 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the group treated with psychostimulant agents, the level of overall functioning increased significantly more than in the group receiving non-psychostimulant medication especially at six months and at two years from the start of treatment administration [10][11][12].…”

Section: Discussionmentioning

confidence: 99%

“…Today, the medical treatment of ADHD is represented by psychostimulant-Methylphenidate, and non-psychostimulant drugs-Atomoxetine [6,[10][11][12]. In the absence of adequate treatment, ADHD has an unfavourable prognosis and may result in complications.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, it can be said that both types of treatment are effective in reducing the aggressiveness of ADHD symptoms, but psychostimulants bring improvements faster and over a longer period of time [6,12].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of Psychostimulant and Non-Psychostimulant Drug Therapy in the Attention Deficit Hyperactivity Disorder

et al. 2021

View full text Add to dashboard Cite

Attention Deficit Hyperkinetic Disorder (ADHD) is a neurobiological behavioral disorder of the child, adolescent, and adult characterized by problems of concentration, hyperactivity, and impulsivity caused by an imbalance of chemical neurotransmitters in the brain—dopamine and noradrenaline. ADHD first-line drugs are divided in psychostimulant, as Methylphenidate and Amphetamines and non-psychostimulant medications-Atomoxetine (the only representative non-psychostimulant medication approved in our country in children and adolescents). The purpose of our research was to assess the clinical evolution of patients with ADHD based on the drug treatment that is administered: psychostimulant or non-psychostimulant. Both psychostimulant—Methylphenidate, and non-psychostimulant therapy—Atomoxetine, proved to significantly improve the symptoms of attention deficit hyperkinetic disorder. There was a significant reduction in the severity of ADHD symptoms at six months and at one year from the start of treatment in the case of the psychostimulant group, whereas in the non-psychostimulant group, the significant reduction in severity of symptomatology occurs only at six months after the start of treatment. We can conclude that both types of drugs are effective in reducing the severity of symptoms and in improving the clinical condition of patients with ADHD, but the comparative analysis of the two groups demonstrated that significantly better results are obtained with psychostimulant treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of Psychostimulant and Non-Psychostimulant Drug Therapy in the Attention Deficit Hyperactivity Disorder

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The response rates in the current program were similar to those observed in other patient feedback surveys administered in many chronic disease states. For example, in a parental survey that assessed the treatment effect of lisdexamfetamine dimesylate for pediatric attention deficit hyperactivity disorder, 29.5 % of the baseline participants completed the 6-week follow-up survey [ 20 ], whereas, 23.2 % of the baseline survey participants completed both follow-ups in the current program.…”

Section: Discussionmentioning

confidence: 99%

Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program

Crayton

Sidovar

Wulf³

et al. 2014

Patient

View full text Add to dashboard Cite

BackgroundDalfampridine extended-release tablets (dalfampridine-ER; in Europe, prolonged-release fampridine, and elsewhere, fampridine modified or fampridine sustained release), 10 mg twice daily, are available for the treatment of improvement of walking in patients with multiple sclerosis, as demonstrated by an increase in walking speed. On-drug patient perspectives and experiences are valuable to understand and manage this patient population.ObjectiveThe objective of this study was to examine perspectives and experiences of patients receiving dalfampridine-ER in a real-world setting.MethodsStep Together, an ongoing program that captures real-world patient experience with dalfampridine-ER treatment, consists of a survey administered at baseline (before dalfampridine-ER initiation) and at 30 (first follow-up) and 60 days (second follow-up) after initiation. The survey includes modified versions of the 12-item Multiple Sclerosis Walking Scale (mMSWS-12) and the Sheehan Disability Scale (mSDS) to assess walking ability and functional impairment, respectively.ResultsAs of September 2013, 2,248 patients participated in the baseline survey and 522 completed both follow-up surveys (completers). Among the completers, improvements in walking ability and function relative to baseline were significant at both follow-ups as measured by mMSWS-12 and mSDS scores, respectively. Notably, 69–74 % of completers at both follow-ups had improved mMSWS-12 scores, with scores greater than the range considered to be minimally clinically significant. Patients who completed the program expressed satisfaction with overall dalfampridine-ER treatment, and 69 % indicated that the survey would help them communicate better with their healthcare providers.ConclusionResults highlight the utility of patient-reported outcomes in the assessment of patient perspective and experience, providing a useful supplement to traditional objective measures used in clinical studies.Electronic supplementary materialThe online version of this article (doi:10.1007/s40271-014-0102-z) contains supplementary material, which is available to authorized users.

show abstract

“…Antonucci et al assessed parents’ perceptions regarding the impact of ADHD and use of LDX in children via surveys (n > 11,000) in a real-world setting 61. Parents reported significant improvements in symptoms that caused substantial interference with school activities, homework, and family and social interactions ( P < 0.01).…”

Section: Clinical Applications and Place In Therapymentioning

confidence: 99%

Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder

Najib¹

2012

AHMT

View full text Add to dashboard Cite

Attention-deficit/hyperactivity disorder is one of the most common neurobehavioral disorders defined by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity. Symptoms begin in childhood and may persist into adolescence and adulthood. Currently available pharmacological treatment options for attention-deficit/hyperactivity disorder in children and adolescents include stimulants that are efficacious and well tolerated; however, many of these preparations require multiple daily dosing and have the potential for abuse. Lisdexamfetamine dimesylate, the first prodrug stimulant, was developed to provide a longer duration of effect. It demonstrates a predictable delivery of the active drug, d-amphetamine, with low interpatient variability, and has a reduced potential for abuse. A literature search of the MEDLINE database and clinical trials register from 1995–2011, as well as relevant abstracts presented at annual professional meetings, on lisdexamfetamine dimesylate in children and adolescents were included for review. This article presents the pharmacokinetic profile, efficacy, and safety of lisdexamfetamine dimesylate for the treatment of attention-deficit/hyperactivity disorder in children and, more recently, in adolescents.

show abstract

Assessing Effects of Treatment With Lisdexamfetamine Dimesylate for Pediatric ADHD Using a Parental Survey

Cited by 4 publications

References 9 publications

Effectiveness of Psychostimulant and Non-Psychostimulant Drug Therapy in the Attention Deficit Hyperactivity Disorder

Effectiveness of Psychostimulant and Non-Psychostimulant Drug Therapy in the Attention Deficit Hyperactivity Disorder

Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program

Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder

Contact Info

Product

Resources

About